AIFA Board of Directors approves the reimbursability of 2 medicines

News Healthcare & Pharma Reports

Date: 11th Apr, 2025 Source: Italian Medicines Agency (AIFA) Country: Italy Original Source

Brief

On April 10, 2025, the Italian Medicines Agency's Board of Directors approved the reimbursability of two medicines. Iqirvo (elafibranor) will be reimbursed for treating patients with primary biliary cirrhosis (CBP), a rare and progressive liver disease. Orserdu (elacestrant) is also being made available, indicated in monotherapy for postmenopausal women and men with locally advanced or metastatic breast cancer.

This content is restricted.

Highlights content goes here...

This content is restricted.

Italian Medicines Agency (AIFA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

AIFA Board of Directors approves the reimbursability of 2 medicines

Brief

Italian Medicines Agency (AIFA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

AIFA Board of Directors approves the reimbursability of 2 medicines

Brief

Italian Medicines Agency (AIFA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.